伦瓦提尼
医学
肝细胞癌
化疗
栓塞
外科
肝细胞癌
肿瘤科
放射科
内科学
索拉非尼
作者
Takeshi Utsunomiya,Katsunori Sakamoto,Miku Iwata,Chihiro Ito,Akimasa Sakamoto,Takashi Matsui,Mikiya Shine,Yusuke Nishi,Mio Uraoka,Tomoyuki Nagaoka,Kei Tamura,Naotake Funamizu,Kohei Ogawa,Riko Kitazawa,Yasutsugu Takada
出处
期刊:PubMed
日期:2022-12-01
卷期号:49 (12): 1365-1367
摘要
A 57-year-old man was treated with lenvatinib for unresectable hepatocellular carcinoma(HCC). Thereafter, the tumor marker levels decreased, and the tumor became resectable. The patient underwent portal vein embolization followed by laparoscopic extended left lobectomy. The patient's postoperative course was uneventful, and the tumor marker levels remained within the normal range. No recurrence was observed 3 months after surgery. In recent years, the use of systemic chemotherapy with drugs, such as lenvatinib, followed by conversion surgery has been reported in some cases of unresectable HCC. The present case reports successful conversion surgery following lenvatinib treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI